A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

• প্রধান লেখক: Azra Hussaini (লেখক), Rajat Mukherjee (লেখক), Dina M. Berdieva (লেখক), Christen Glogowski (লেখক), Richard Mountfield (লেখক), Peter T.C. Ho (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2020-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

The purpose of this study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of BOS161721, a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody that inhibits interleukin‐21 (IL‐21) bioactivity. This randomized, single‐cente...